Table 2 Distribution of antibiotic treatment according to acquisition group*
P. aeruginosa acquisition n= 20 (%) | No P. aeruginosa acquisition n= 106 (%) | Total n= 126 (%) | |
|---|---|---|---|
Antibiotics active against P. aeruginosa | 10 (50) | 57 (54) | 67 (53) |
Aminosides | 6 (30) | 17 (16) | 23 (18) |
Ureido/carboxypenicillins | 5 (25) | 19 (18) | 24 (19) |
Piperacillin-tazobactam | 5 (25) | 12 (11) | 17 (13) |
Ticarcillin-clavulanic acid | 0 (0) | 7 (7) | 7 (6) |
Antipseudomonal cephalosporins | 3 (15) | 13 (12) | 16 (13) |
Ceftazidime | 3 (15) | 6 (6) | 9 (7) |
Cefepime | 0 (0) | 7 (7) | 7 (6) |
Carbapenems | 4 (20) | 12 (11) | 16 (13) |
Fluoroquinolones | 7 (35) | 33 (31) | 40 (32) |
Others | 1 (5) | 3 (3) | 4 (3) |
Fosfomycin | 0 (0) | 2 (2) | 2 (2) |
Colomycin | 1 (5) | 1 (1) | 2 (2) |
Antibiotics not active against P. aeruginosa | 14 (70) | 85 (80) | 99 (79) |
Glycopeptides | 5 (25) | 30 (28) | 35 (28) |
Non-antipseudomonal penicillins | 4 (20) | 43 (41) | 47 (37) |
Penicillin G | 0 (0) | 1 (1) | 1 (1) |
Penicillin M | 0 (0) | 2 (2) | 2 (2) |
Amoxicillin | 1 (5) | 3 (3) | 4 (3) |
Amoxicillin-clavulanic acid | 3 (15) | 37 (35) | 40 (32) |
Non-antipseudomonal cephalosporins (cefotaxim; cefuroxim; ceftriaxon) | 10 (50) | 23 (22) | 33 (26) |
Macrolides | 5 (25) | 12 (11) | 17 (13) |
Other | 2 (10) | 18 (17) | 20 (16) |
Pristinamycin | 0 (0) | 3 (3) | 3 (2) |
Metronidazole | 0 (0) | 10 (9) | 10 (8) |
Cotrimoxazole | 1 (5) | 1 (1) | 2 (2) |
Rifampicin | 1 (5) | 4 (4) | 5 (4) |